Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1996-06-07
1998-06-09
Wilson, James O.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 271, 536 272, 536 2721, 536 2723, 536 276, 536 2762, 536 2763, 536 277, C07H 1916
Patent
active
057635978
ABSTRACT:
This invention relates to adenosine kinase inhibitors and to nucleoside activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.
REFERENCES:
patent: 4455420 (1984-06-01), Kazlauskas
patent: 4904666 (1990-02-01), Friebe et al.
Achterberg, Peter W., et al., Biochem. J. (1986) 235, 13-17.
Bontemps, Francoise et al., Proc. Natl. Acad. Sci. USA vol. 80, pp. 2829-2833, May 1983 Biochemstry.
Burke, Stephan P. et al., Journal of Neurochemistry, vol. 51, No. 5, 1988.
Caldwell, Ian C., et al. Cancer Chemotherapy Reports (Part 2) vol. 2, No. 1, Apr. 1971.
Cheng, C.C., et al., The Journal of Organic Chemistry vol. 21, No. 11, Nov. 1956.
Cottam, Howard B., et al. J. Med. Chem. 1984, 27, 1119-1127.
Davies, Les P., et al. Biochemical Pharmacology, vol. 33, No. 3, pp. 347-355, 1984.
Davies, Les P., et al. Biochemical Pharmacology, vol. 35, No. 18, pp. 3021-3029, 1986.
Firestein, Gary S., et al. The Journal of Immunology, 1995, 154, 326-334.
Flynn, Bernard L., et al. Nucleosides & Nucleotides, 10(4), 763-779 (1991).
Green, Richard D. Journal of Supramolecular Structure 13:175-182 (1980) Membrane Transport & Neuroreceptors 109-116.
Henderson, J.F., et al. Cancer Chemotherapy Reports, Part 2, vol. 3:71-85 No. 1, Nov. 1972.
Kobayashi, Shigeru, Chem. Pharm. Bull., 21(5) 941-951 (1973).
Miller, Richard L., et al., The Journal of Biological Chemistry, vol. 254, No. 7 (1979) pp. 2346-2352.
Newby, Andrew C., et al. Biochem. J., (1983) 214, 317-323.
Pak, M.A. et al., Society for Neuroscience Abstracts, vol. 20, 1994.
Prescott, M. et al., Nucleosides & Nucleotides, 8(2), 297-303 (1989).
Rosemeyer, Helmut et al., Helvetica Chimica Acta, vol. 71 (1988) pp. 1573-1585.
Rosengren, Sanna, et al., The Journal of Immunology, 1995, 154: 5444-5451.
Sciotti, Veronica M., et al., Journal of Cerebral Blood Flow & Metabolism, 13:201-207 (1993).
Snyder, Joseph R., et al., Carbohydrate Research, 163 (1987) 169-188.
Sosnowski. M., et al., The Journal of Pharmacology & Experimental Therapeutics, vol. 250, No. 3 (1989).
Swinyard, Ewart A. et al., Antiepileptic Drugs, Third Edition (1989) pp. 85-102.
White, I.D., Society for Neuroscience Abstracts, vol. 20, 1994.
Wu, Shi-Qu, et al., Cytobios, 50 7-12, 1987.
Yamada, Yasukazu et al., Biochimica et Biophysica Acta, 660 (1981) 36-43.
Phillis, John W., et al., Life Sciences, vol. 53, pp. 497-502 (1993).
Zoref-Shani, Esther, et al.,Mol Cell Cardiol, 20, 23-33 (1988).
Browne Clinton E.
Castellino Angelo J.
Erion Mark D.
Gomez Galeno Jorge E.
Ugarkar Bheemarao G.
Metabasis Therapeutics, Inc.
Wilson James O.
LandOfFree
Orally active adenosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally active adenosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally active adenosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2200717